Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

297.19
Delayed Data
As of Dec 02
 +1.41 / +0.48%
Today’s Change
223.02
Today|||52-Week Range
333.65
-2.99%
Year-to-Date
Why Eli Lilly Shares Lost 8% in November
8:13am / MotleyFool.com - Paid Partner Content
Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Mine Field
Nov 30 / TheStreet.com - Paid Partner Content
John Paulson's Largest 3rd Quarter Trades
Dec 01 / GuruFocus News - Paid Partner Content
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for...
Nov 30 / Zacks.com - Paid Partner Content
GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?
Dec 01 / Zacks.com - Paid Partner Content
Visualizing Financial Trends With Interactive Charts, Other Topics
Nov 29 / GuruFocus News - Paid Partner Content
3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
Dec 01 / MotleyFool.com - Paid Partner Content
Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
Nov 25 / Zacks.com - Paid Partner Content
Better Buy: Biogen Inc. vs. Amgen
Nov 30 / MotleyFool.com - Paid Partner Content
Lilly's Alzheimer Drug Fails Phase III Study, Stock Down
Nov 24 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close295.78
Today’s open296.53
Day’s range293.04 - 299.95
Volume1,429,360
Average volume (3 months)1,626,213
Market cap$64.7B
Dividend yield--
Data as of 3:59pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+18.69%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)+8.60%
P/E ratio16.8
Price/Sales7.60
Price/Book6.93

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences-0.42-0.58%
AMGNAmgen+1.62+1.14%
ILMNIllumina Inc+0.18+0.14%
TECHBio-Techne Corp-0.47-0.44%
Data as of 3:59pm ET, 12/02/2016

Financials

Next reporting dateFebruary 1, 2017
EPS forecast (this quarter)$5.00
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs